World Investment Advisors LLC Purchases Shares of 19,358 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

World Investment Advisors LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 19,358 shares of the biotechnology company’s stock, valued at approximately $2,418,000.

A number of other hedge funds have also recently modified their holdings of the company. Innealta Capital LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $31,000. Sunbelt Securities Inc. increased its position in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth about $43,000. Finally, Riggs Asset Managment Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $123.71 on Friday. The company has a market cap of $11.82 billion, a price-to-earnings ratio of 98.97 and a beta of 0.77. The business’s fifty day simple moving average is $123.12 and its two-hundred day simple moving average is $131.43. Sarepta Therapeutics, Inc. has a 12 month low of $89.92 and a 12 month high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Activity

In other news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Raymond James reissued an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Needham & Company LLC decreased their target price on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a research report on Wednesday, November 27th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. UBS Group upped their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.